• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Liver international >Aminopyrine breath test predicts liver‐related events and death in HCV‐related cirrhosis on SVR after DAA therapy
【24h】

Aminopyrine breath test predicts liver‐related events and death in HCV‐related cirrhosis on SVR after DAA therapy

机译：Aminopyrine breath test predicts liver‐related events and death in HCV‐related cirrhosis on SVR after DAA therapy

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Abstract Background & Aims In patients with hepatitis C virus (HCV)‐related advanced cirrhosis, the effects of sustained virological response (SVR) by direct antiviral agents (DAAs) on decompensation and liver deaths are less clearcut, since up to 30% of patients do not improve, and no predictors of outcome have been identified. We used 13 C‐aminopyrine breath test (ABT) to assess whether its changes can predict liver‐related outcomes after DAA treatment in patients with HCV cirrhosis. Methods Fifty consecutive patients with HCV cirrhosis were enrolled. Patients were included if they had Child A cirrhosis at risk for decompensation – defined as Child A6 (N?=?22, 44%) or previous decompensation (N?=?7, 14%) – or Child B cirrhosis (N?=?21, 42%) eligible for DAA‐based antiviral therapy. ABT was performed at baseline and 12?weeks after the end of antiviral therapy. Patients received sofosbuvir‐based regimens. Results Aminopyrine breath test was available for all 50 patients at baseline. The 120’ cumulative dose was directly associated at regression analysis only with albumin levels ( P ?=?.001). ABT was available at follow‐up week 12 for 41 patients (FUW12), all with SVR, and followed for a median of 25.2?months (range 12.2‐32.1?months). Lower ? ABT – defined as changes of 120’ cumulative dose from FUW12 to baseline – (HR 0.97, 95% CI 0.94‐0.99; P ?=?.02) and FUW12 hepatic encephalopathy (HR 19.0, 95% CI 1.16‐310.3; P ?=?.03) were the only independent predictors of liver events/death at multivariate Cox regression analysis. The AUC of ? ABT was good (0.87, 95% CI 0.75‐0.97), with a delta ≥0% well discriminating patients at lower vs patients at higher risk of liver‐related events/death ( P ??.001). Conclusions In patients with advanced HCV cirrhosis who achieve SVR with DAA, ? ABT assists in assessing the residual likelihood of liver‐related events and deaths after viral cure.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号